DNA X Completes $2.5M Series B Sale, Projects Nasdaq Equity Compliance
SONM sits 34% above its 52-week low of $2.521 on light trading volume (0.3× avg).
Summary
DNA X completed its Series B preferred stock sale, raising $2.5 million and projecting stockholders' equity above the Nasdaq minimum, potentially resolving its delisting risk.
Key Events · Financing and Capital Events · SONM
-
Series B Sale Completed
Sold remaining 416,667 shares of Series B Preferred Stock for $2.5 million cash on August 7, 2026, completing the financing announced July 2.
-
Nasdaq Equity Compliance Projected
Pro forma stockholders' equity of $5.84 million as of August 7, 2026, exceeds the $2.5 million Nasdaq minimum, addressing the May 27 delisting notice.
-
Financing Proceeds Detail
The $2.5 million from this tranche adds to the $5.6 million raised in July, totaling $8.1 million in new financing.
-
Nasdaq Determination Pending
Company awaits formal Nasdaq confirmation of compliance; no timeline provided.
Analysis · SONM · Manufacturing
The remaining 416,667 Series B preferred shares were sold for $2.5 million, completing the financing announced in July. Stockholders' equity is now projected at $5.84 million, above the $2.5 million Nasdaq minimum, which addresses the delisting notice from May. This removes a major overhang, though Nasdaq has not yet formally confirmed compliance.
At the time of this filing, SONM was trading at $3.39 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $5M. The 52-week trading range was $2.52 to $16.97. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.